Identification of ER/SR resident proteins as biomarkers for ER/SR calcium depletion in skeletal muscle cells

Lacey K. Greer1, Katherine G. Meilleur2, Brandon K. Harvey1* and Emily S. Wires1*

Abstract

Background: Aberrations to endoplasmic/sarcoplasmic reticulum (ER/SR) calcium concentration can result in the departure of endogenous proteins in a phenomenon termed exodosis. Redistribution of the ER/SR proteome can have deleterious effects to cell function and cell viability, often contributing to disease pathogenesis. Many proteins prone to exodosis reside in the ER/SR via an ER retention/retrieval sequence (ERS) and are involved in protein folding, protein modification, and protein trafficking. While the consequences of their extracellular presence have yet to be fully delineated, the proteins that have undergone exodosis may be useful for biomarker development. Skeletal muscle cells rely upon tightly coordinated ER/SR calcium release for muscle contractions, and perturbations to calcium homeostasis can result in myopathies. Ryanodine receptor type-1 (RYR1) is a calcium release channel located in the SR. Mutations to the RYR1 gene can compromise calcium homeostasis leading to a vast range of clinical phenotypes encompassing hypotonia, myalgia, respiratory insufficiency, ophthalmoplegia, fatigue and malignant hyperthermia (MH). There are currently no FDA approved treatments for RYR1-related myopathies (RYR1-RM).

Results: Here we examine the exodosis profile of skeletal muscle cells following ER/SR calcium depletion. Proteomic analysis identified 4,465 extracellular proteins following ER/SR calcium depletion with 1,280 proteins significantly different than vehicle. A total of 54 ERS proteins were identified and 33 ERS proteins significantly increased following ER/SR calcium depletion. Specifically, ERS protein, mesencephalic astrocyte-derived neurotrophic factor (MANF), was elevated following calcium depletion, making it a potential biomarker candidate for human samples. Despite no significant elevation of MANF in plasma levels among healthy volunteers and RYR1-RM individuals, MANF plasma levels positively correlated with age in RYR1-RM individuals, presenting a potential biomarker of disease progression. Selenoprotein N (SEPN1) was also detected only in extracellular samples following ER/SR calcium depletion. This protein is integral to calcium handling and SEPN1 variants have a causal role in SEPN1-related myopathies (SEPN1-RM). Extracellular presence of ER/SR membrane proteins may provide new insight into proteomic alterations extending beyond ERS proteins. Pre-treatment of skeletal muscle cells with bromocriptine, an FDA approved drug recently found to have anti-exodosis effects, curbed exodosis of ER/SR resident proteins.

Conclusion: Changes to the extracellular content caused by intracellular calcium dysregulation presents an opportunity for biomarker development and drug discovery.

Keywords: Exodosis, Ryanodine receptor isoform-1, Myopathy, Skeletal muscle, Bromocriptine, MANF, SEPN1, SIL1

Introduction

The endoplasmic/sarcoplasmic reticulum (ER/SR) is the main reservoir for intracellular calcium [1], serving an imperative role for muscle contraction and relaxation.
This extensive tubular network is also responsible for a myriad of cellular functions including, protein synthesis [2], protein modification [2], protein degradation [3], lipid metabolism [4], carbohydrate metabolism [5], and xenobiotic detoxification [6]. The SR is a specialized extension of the ER and coordinates the release of calcium during muscle contraction [7]. Depletion of ER/SR calcium causes the secretion of ER/SR resident protein in phenomenon described as exodosis [8].

Next, we sought to use a more quantitative proteomics approach to identify additional extracellular ERS proteins by mass spectrometry (Fig. 2). Of the 4,465 extracellular proteins identified, 1,280 proteins significantly changed following Tg treatment. 54 corresponded to ERS proteins previously linked to ER calcium depletion exclusively, as opposed to a general ER stress response [1, 8]. To test if this observation extended to skeletal muscle cells, we examined extracellular MANF following an 8-h treatment with the ER stress inducer, tunicamycin (Tm). Tm did not elicit elevated extracellular MANF despite prompting a robust increase in unfolded protein response (UPR) and ER stress gene expression that was similarly observed in Tg treatment (Additional file 3: Fig. S3).

Results
Calcium dysregulation elicits exodosis in human skeletal muscle cells

Previously, disruption of ER/SR calcium in primary skeletal muscle elicited the secretion of GLuc-SERCaMP, an exogenous reporter of exodosis. Curious if this observation extended to endogenous ERS proteins, human skeletal muscle cells were treated with 100 nM of thapsigargin (Tg) or vehicle for 8 h. Tg is a pharmacological inhibitor of SR calcium ATPase (SERCA) commonly used to deplete ER/SR calcium reservoir. Tg increased general extracellular protein content (Additional file 1: Fig. S1A) as well as a subset of ERS proteins previously shown to undergo exodosis [8], including mesencephalic astrocyte derived neurotrophic factor (MANF), protein disulfide isomerase (PDIA1/P4HB), and liver carboxylesterases 1 and 2 (CES1 and CES2) (Fig. 1A–C). Exodosis has been previously linked to ER calcium depletion exclusively, as opposed to a general ER stress response [1, 8]. To test if this observation extended to skeletal muscle cells, we examined extracellular MANF following an 8-h treatment with the ER stress inducer, tunicamycin (Tm). Tm did not elicit elevated extracellular MANF despite prompting a robust increase in unfolded protein response (UPR) and ER stress gene expression that was similarly observed in Tg treatment (Additional file 3: Fig. S3).

There is an incentivized need to expedite orphan drug development and drug repurposing for the therapeutic intervention of rare diseases [21]. Henderson and colleagues recently screened 9,501 compounds approved by U.S. and numerous international regulatory agencies and characterized several for their anti-exodosis properties [10]. Given the propensity for SR calcium leak in RYR1 variants, we sought to examine skeletal muscle cells for exodosis following ER/SR calcium depletion. Herein we describe a proteomic approach to identify potential biomarkers reflective of calcium dysregulation and investigate anti-exodosis effects of bromocriptine, an FDA-approved drug recently shown to have anti-exodosis properties.
In addition to ERS proteins, several non-ERS proteins were also released from the cell in response to ER/SR calcium depletion. Of note, selenoprotein N (SEPN1) was the most abundant non-ERS extracellular protein detected based on previously established ERS criteria [8, 9] (Fig. 2). Another example from our mass spectrometry data of a non-ERS protein with increased extracellular content is nucleotide exchange factor SIL1. SIL1 is a co-factor of ERS protein, HSPA5 (BiP) which displayed a 5.6115-fold increase following ER/SR calcium depletion (Additional file 1: Fig. S1B).

**Bromocriptine attenuates exodosis in skeletal muscle cells**

Variants within the *RYR1* gene have a causative role in the development of malignant hyperthermia (MH), a rare, but serious condition characterized by sustained muscle contraction, hyperthermia, and rhabdomyolysis in response to halogenated anesthetics [15]. Dantrolene is a RYR antagonist that stabilizes receptor resting state by increasing Mg^{2+} affinity and is currently the only FDA approved drug for MH, although a RYR1-selective inhibitor, 6,7-(methylenedioxy)-1-octyl-4-quinolone-3-carboxylic acid, was recently shown to
be effective in murine MH models [20, 22]. Henderson et al., 2021 recently described a high throughput screen using the exodosis reporter Gaussia luciferase-secreted ER calcium modulated protein (GLuc-SERCaMP) and identified several FDA approved drugs effective in attenuating exodosis including dantrolene [10]. Of the additional compounds identified, bromocriptine, verapamil, dextromethorphan, and diltiazem partially attenuated SERCaMP release in primary skeletal muscle cells pre-treated for 30 min prior to 8 h 100 nM Tg treatment [10]. Moreover, bromocriptine consistently displayed anti-exodosis effects in models of stroke and Wolfram syndrome, prompting us to test its ability to reduce extracellular ERS proteins in skeletal muscle cells [10]. Towards this, we pre-treated skeletal muscle cells with 20 µM bromocriptine or 50 µM dantrolene 30 min prior to Tg treatment. No difference in overall extracellular protein content was observed among pre-treatment with 20 µM bromocriptine or 50 µM dantrolene (Fig. 3A). However, pre-treatment with 20 µM bromocriptine for 30 min prior to Tg-induced ER/SR calcium depletion significantly reduced the amount of extracellular ERS proteins (Fig. 3B). Dantrolene pre-treatment exhibited a modest attenuation of ERS proteins, albeit to a lesser extent than bromocriptine (Fig. 3B; Additional file 2: Fig. 2A, B). One ERS protein, MANF, was increased in media evidenced by mass spectrometry data, western blot, gene expression analysis, and homogenous time-resolved fluorescence (HTRF) assays (Figs. 1A, 2, 3D, E; Additional file 1: Fig. 1B, Additional file 2: Fig. 2B, Additional file 3: Figure S3). Increased secretion of MANF has been previously observed during exodosis [8, 10]. Extracellular MANF increased approximately 3.8-fold upon ER/SR calcium depletion in skeletal muscle cell line (Additional file 1: Fig. S1B). Pre-treatment with 20 µM bromocriptine for 30 min prior to 100 nM Tg for 8 h significantly reduced extracellular MANF levels (Fig. 3C–E). Surprisingly, dantrolene did not attenuate extracellular MANF levels despite previously reported attenuation in SH-SY5Y neuroblastoma cell line, suggesting varying cell-specific responses (Fig. 3C–E) [8].

**MANF is elevated in aging RYR1-RM- affected individuals**

Given that Tg-induced ER/SR calcium depletion of human skeletal cell line elicited elevated extracellular MANF levels, we next sought to determine if circulating MANF levels were upregulated in RYR1-RM- affected individuals. Homogenous time-resolved fluorescence (HTRF) technology permits the measurement of biomarkers and analytes in the nanogram range from cell culture as well as human CSF, sera, blood, and plasma [23]. Commercially available MANF HTRF was used to assess levels of circulating MANF from human plasma samples obtained from a clinical trial NCT02362425 prior to intervention [24]. While no significant difference was observed among healthy volunteers and RYR1-RM- affected individuals, there was a significant correlation between circulating MANF levels and increased age observed only in RYR1-RM-affected individuals (Fig. 4A–C). No correlation was detected between genotype or sex and MANF levels (data not shown). Collectively, our data support MANF as a biomarker of exodosis, with potential use for RYR1-RM progression and therapeutic intervention. Additional ERS proteins were identified and may serve as biomarkers of disrupted ER/SR calcium homeostasis and altered proteostasis in skeletal muscle cells, although further investigation is warranted.
Discussion

Herein we describe ER/SR calcium dysregulation promotes exodosis in a human skeletal muscle cell line. Perturbations to ER/SR calcium contribute to the pathophysiology of vast disease states [25], thus presenting a substantial need for the identification of clinical biomarkers and calcium-stabilizing therapeutics.

Despite small patient populations, there are approximately 7,000 rare diseases affecting 350 million patients globally, with a cumulative estimation being greater than HIV and cancer combined [26]. Most rare diseases still lack treatment despite recent efforts to advance rare disease research and accelerate drug discovery [26]. Towards the development of therapeutic modalities, protein-based therapeutics specific to extracellular targets are a viable option [26]. Having the ability to modulate extracellular targets first requires their identification, thus highlighting the translational appeal of investigating exodosis.

Skeletal muscle cells exhibited an exodosis phenotype specifically upon ER/SR calcium dysregulation evidenced by Tg-induced release and not Tm, despite UPR activation observed with treatment of both compounds. While the consequences for redistributing the resident ER/SR proteins from intracellular to extracellular space need to be determined, circulating ERS proteins have been identified in human plasma from a variety of diseases associated with ER calcium dysregulation [27–30]. Many extracellular ERS proteins identified in our analyses are molecular chaperones that interact with, stabilize, or assist other proteins reach functional conformation (e.g., HSP, PDI, CALR) [31]. Protein disulfide isomerases (PDIs), specifically, are a family of ER/SR-resident...
proteins responsible for the maintenance of disulfide bonds, thus promoting naïve protein conformation [32]. The PD1 gene family encompasses 21 genes that all contain a thioredoxin domain, but are quite diverse in size, expression, and function [33]. Increased extracellular PDIA1/P4HB, PDIA5, PDIA4, and PDIA3 were identified in mass spectrometry analysis (Additional file 1: Fig. 1b). Extracellular PDIA3 has been implicated as a mediator of myoblast differentiation and fusion during muscle regeneration [34]. Muscle regeneration is integral to the restoration of physiological function and when impaired, as often observed in myopathies, can result in weakened function [34]. Moreover, PDIs are upregulated upon unfolded protein response (UPR) activation, serving as a molecular chaperone set forth to alleviate protein misfolding through rearrangement of incorrect disulfide bonds via isomerase activity or through the degradation of misfolded proteins via ER associated degradation (ERAD) [35, 36]. Relocation of molecular chaperones to the extracellular environment suggests a loss of intracellular proteins critical to maintaining proteostasis, perhaps exacerbating disease progression and symptoms experienced by RYR1-RM- affected individuals.

Liver carboxylesterases (CES1 and CES2) are ERS proteins that undergo exodosis in response to ER calcium depletion [37]. Our lab previously developed an extracellular esterase assay as an indicator of ER calcium depletion in the liver caused by high fat diet [38]. Although predominantly expressed in liver, CES2 has also been detected in bladder, heart, small intestine, and skeletal muscle [39]. The function of CES2 in skeletal muscle has not been studied. Here, using mass spectrometry, we found that CES2 protein is increased in the extracellular space following ER/SR calcium depletion. We also detected increased CES1/2 activity in the media of thapsigargin treated skeletal muscle cells. Our data suggest that CES2 undergoes exodosis in skeletal muscle cells and further studies into the function of CES2 in skeletal muscle are warranted.

One ERS protein in particular, MANF is an ER stress inducible protein that exhibits vast trophic activity among various tissues and pathological conditions [40]. The secretion of MANF is triggered by ER stress associated
with ER calcium depletion [8, 41]. We observed an increase in extracellular MANF levels following ER/SR calcium depletion [42]. Prolonged ER stress can contribute to muscle atrophy, inflammation, insulin resistance, and disrupted proteostasis [43]. Increased release of pro-inflammatory cytokines IL-6 and IL-1 from cultured myotubes and B-lymphocytes has been observed in MH-causing RYR1 mutations [44, 45], suggesting a potential interplay with the immune system. There is a fine balance between local, transient inflammation that stimulates pro-myogenic muscle repair and wide-spread, chronic inflammation that diminishes regenerative capability [46]. While the function of MANF in skeletal muscle cells is limited, its anti-inflammatory effects are well documented [40]. Our data from human patients with RYR1 mutations show a correlation of age and increased plasma levels of MANF. Whether the elevated MANF is indicating ER/SR calcium depletion in skeletal muscle is not clear, however, human patients without the mutations did not see an age-related increase in plasma MANF levels. Also, decreased circulating MANF levels have been reported in human and rodent sera in an age-dependent manner [47], contrary to our observation of age-dependent MANF increase specific to RYR1-RM-affected individuals. While MANF displays biomarker potential for the RYR1 community, we recognize the limited sample size in the current study, emphasizing the need for more rare disease natural history studies. However, our collective data support MANF as a potential biomarker of skeletal muscle diseases associated with ER/SR calcium dysregulation. Additional studies are needed to further examine the relationship of MANF and RYR1-related myopathies.

In addition to identifying ERS-containing proteins, several non-ERS proteins were also detected outside of the cell following ER/SR calcium depletion. For example, SEPN1 was the overall protein (ERS and non-ERS) that showed the highest increase in media of cells treated with thapsigargin. This is largely due to no detectable SEPN1 protein in some vehicle samples and detectable signal in Tg-treated samples. SEPN1 is a type II ER transmembrane protein with reductase activity sensitive to ER calcium fluctuations [48]. SEPN1 has been proposed as an intermediary between calcium sensing and calcium refilling through SERCA2 interactions. Single amino acid mutations in SEPN1 are associated with SEPN1-related myopathy (SEPN1-RM), chronic ER stress, altered calcium affinity, and impaired SEPN1 conformational change [48]. BioGRID analysis of SEPN1 indicated interactions with ERS proteins, TNRC5 and OS9, both of which displayed a 4.247-fold and 1.15-fold increase in response to ER SR calcium depletion, respectively (Additional file 1: Fig. 1B). Perhaps SEPN1 is cleaved during ER/SR calcium depletion and its interaction with ERS proteins is sufficient to confer its release from the cell, ultimately exacerbating alterations to proteome composition. To our knowledge, this is the first to report the presence of extracellular SEPN1 in response to ER/SR calcium depletion. This may present insight into SEPN1 handling in individuals with SEPN1-RM and poses biomarker potential. Interestingly, SEPN1-RM shares some clinical and histopathologic features with RYR1-RM [49]. Mass spectrometry or biomarker analyses of plasma from SEPN1-RM individuals and healthy volunteers may be warranted to corroborate our in vitro findings.

A second non-ERS proteins that was elevated following ER/SR calcium depletion is SIL1. SIL1 is a co-factor of ERS protein, HSPA5 (BiP) [50], which displayed a 5.6115-fold increase following ER/SR calcium depletion (Additional file 1: Fig. 1B). Causative mutations in SIL1 are associated with the rare genetic disorder Marinosco-Sjögren syndrome (MSS) [51]. MSS is characterized by intellectual deficits, congenital cataracts, and myopathy, with some genotype–phenotype data indicating protein instability, protein aggregation, and ER stress [52]. Proteomic profiling of wild-type and Sil1GT mice indicated perturbations to muscle physiology evidenced by decreased expression of proteins associated with insulin receptor signaling and glucose metabolism, along with increased expression of proteins associated with ER stress and UPR activation [51]. Elucidating ER/SR proteome redistribution can provide insight into disease pathology, biomarker identification, and drug discovery. Implementing the examination of exodosis for compound screens could prove beneficial to developing a multi-faceted therapeutic approach.

Bromocriptine was recently described for its anti-exodosis effects [10]. Here we show that pre-treatment with bromocriptine elicits anti-exodosis effects in skeletal muscle cells. Bromocriptine has been used clinically to treat acromegaly and Parkinson’s disease [53, 54]. Until recently, bromocriptine was thought to act solely on D2 dopamine receptors (D2R), but its effects on exodosis appear to work in a D2R-independent manner, with ability to signal through GPCRs [10]. Although the exact target by which bromocriptine prevents exodosis is currently unknown [10]. Surprisingly, dantrolene exhibited minimal exodosis attenuation unlike previous reports [8, 10]. This may be due to differences in cell lines and varying expression levels of RYR1.

The use of Tg to deplete ER/SR calcium stores is in skeletal muscle cells is well documented [55–59]. Many cellular model systems of RYR1-RM rely on the transfection of mutant RYRI cDNA into HEK293 cells,
which lack several components responsible for the regulation of RYR1 function [60]. Furthermore, many myopathies fall under the rare disease category, making it challenging to procure primary tissue containing clinically reported mutations. We certainly recognize Tg treatment alone does not fully recapitulate the pathophysiology of myopathies, the observed results do suggest a therapeutic role of identified compounds and potential biomarkers in pre-clinical models of ER/SR calcium dysregulation. Further studies are needed to assess the efficacy of these compounds and utility of the biomarkers in the genetic context of RYR1-related myopathies.

**Conclusions**
Understanding alterations to the proteome in the context of diseases may provide insight into pathophysiology and aid in the development of clinical biomarkers. Assessment of exodosis as a pathological cause in RYR-RMs and other diseases associated with ER/SR calcium dysregulation should be considered for future studies and clinical trials.

**Materials and methods**

**Human samples**
Human samples were obtained from the National Institute of Nursing Research, clinical trial identifier NCT02362425. The protocol was approved by the NIH Combined Neuroscience Institutional Review Board. All participants provided written informed consent.

**Cell culture**
T0034 immortalized human skeletal muscle cell line was purchased from ABM. Cell were maintained in Prigrow III medium (ABM), 10% FBS (Sigma), 1% Pen/Strep (Life Technologies) and grown at 37 °C with 5.5% CO₂ in a humidified incubator. Applied extracellular matrix (ABM) was used to coat culture vessels for cell line maintenance and experiments.

For mass spectrometry experiments, cells were seeded in ECM coated 15 cm plates at 8 × 10⁶ cells/plate. Approximately 72 h post-plating, media was removed, cells were rinsed with 1X PBS, and replaced with mass spectrometry assay media (150 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 20 mM HEPES, 1 mM CaCl₂, H₂O). Cells were treated with vehicle (0.5% final DMSO), 20 µM bromocriptine (Tocris), or 50 µM dantrolene (Caymen Chemical) for 30 min, followed by vehicle (0.1% DMSO) or 100 nM Tg (Sigma). After 8 h, 20 mL of media was collected, centrifuged at 1000 rpm for 5 min at room temperature to pellet debris. 15 mL of supernatant was concentrated using 10,000 MW cut-off concentrator conical tubes (Millipore) centrifuged at 4000xg for 40 min at 4 °C as previously described [8]. Protein concentration was determined by DC assay (BioRad). Mass spectrometry analyses were performed by the Johns Hopkins University Mass Spectrometry and Proteomics Core Facility. Briefly, 50 µg of protein was analyzed by TMT pro-16-plex labeling (Thermo Fisher), peptides fractionated by basic reverse phase (bRP) chromatography and analyzed by liquid chromatography tandem mass spectrometry (LC–MS/MS).

**Western blot analysis**
Ten micrograms of protein from concentrated media were collected as described above was set aside for western blot analysis. Proteins were separated on 4–12% Bis–Tris NuPage gels (Thermo Fisher) using MOPS running buffer for 50 min at 200 V. Proteins were transferred to 0.2 µM PVDF membrane using iBlot2 (Thermo Fisher), immunoblotted for MANF (Yenzym #2156; 1:500), P4HB (PDIA1) (Abcam #2792; 1:500) and scanned using Licor system. For protein stain, gels were stained using Simply Blue Safe Stain (Thermo Fisher) and imaged on Azure gel doc system.

**Immunoprecipitation assay**
Media collected from T0034 cells were immunoprecipitated with magnetic Protein A beads (Sure Beads, Bio-Rad) as previously described [8]. Beads were washed with 1X PBS plus 0.1% Tween 20 (PBS-T) and incubated with 2 µg mouse anti P4HB, also known as PDIA1, (Abcam #2792). 400µL of media was incubated with beads for 1 h followed by a series of PBS-T washes as recommended by manufacturer protocol. Samples were eluted in 40µL of 1X LDS (Thermo Fisher), incubated at 70 °C for 10 min, and 18µL was loaded for western blot as described above.

**Esterase activity**
Methods to measure CES1/CES2 activity have been previously described [37]. Briefly, 20µL of media was transferred to black walled, clear bottom plate. Equal volume of 100 µM of fluorescein di-(1-methylcyclopropanecarboxymethyl ether) substrate diluted in mass spectrometry media at pH 5.0 was added to each well. Fluorescence was measured every minute for 60 min at 45 °C using BioTek Synergy H2 plate reader (excitation 485 nm, emission 528 nm).

**MANF homogenous time resolved fluorescence assay**
MANF HTRF assay (CisBio) was used to determine circulating MANF concentration from 16µL of human plasma samples or cell culture media according to
manufacturer’s instructions. Cell culture samples were collected in culture media or mass spectrometry assay media and diluted 1:5 in assay diluent. Samples were read on BioTek Synergy H1 plate reader. 2µL of anti-Human MANF d2 and 2µL of anti-Human MANF Eu cryptate antibody working solutions were added to wells and incubated together in a sealed, white-walled plate for 4 h at room temperature. MANF is detected via a two-antibody FRET-based assay, where MANF-labeled Eu cryptate antibody serves as the donor and MANF-labeled d2 antibody serves as the acceptor. Fluorescence was measured on BioTek Synergy H1 plate reader at 665 nm and 620 nm, 4 h and 24 h following addition of donor and acceptor antibodies (data shown from 4 h read). Sample readouts were compared to a MANF standard curve to determine MANF concentration in each sample.

RNA isolation and droplet digital PCR (ddPCR)

Total RNA was isolated from cultured cells treated with Tg (Sigma), Tm (Sigma), or vehicle (DMSO) using RNAAdvanced Cell V2 (Beckman Coulter) according to the manufacturer’s protocol. RNA concentration was determined using NanoDrop Spectrophotometer (Thermo Fisher). cDNA was generated from 200 ng of RNA in 20µL reaction mix using iScript CDNA synthesis kit (BioRad). Samples were diluted 1:16 in DNase-free water and 5µL was added to 20µL reaction mix consisting of 2X ddPCR Supermix for Probes (No dUTP) (BioRad), 450 nM primers, and either 125 nM probe for reactions using TaqMan Gene Expression Assays or 100 nM probe for reactions using probes previously reported [8, 10]. Samples were partitioned into droplets using QX100 Automated Droplet Generator (BioRad), followed by qPCR using T100 Thermal Cycler (BioRad) with 40 amplification repeats (94 °C for 30 secs, 60 °C for 1 min, repeat 39X, followed by 98 °C for 10 min, and 12 °C constant). Droplets were read using QX200 Droplet Reader (QX200). All values were normalized to the geometric mean of reference genes ubiquitin-conjugating enzyme 2i (Ube2i) and RNA polymerase II (PRNAII). Data is presented as gene expression relative to vehicle treatment. TaqMan Gene Expression Assays reported include GADD34/PPP1r15A (Assay ID# Hs00169585_m1; FAM-MGB), MANF (Assay ID# Hs00180640_m1; VIC-MGB), and CHOP/DDIT3 (Assay ID# Hs01090850_m1; VIC-MGB). Remaining human primers and probes were labeled with FAM/BHQ1 or HEX/BHQ1 (reference genes). Nucleotide sequences and respective accession numbers have been previously reported [8, 10].

Statistical analysis

Results were analyzed using Graph Pad Prism 9. Details about tests can be found in figure legends. Proteome Discoverer 2.4 was used for the generation of biological function pie chart. Data are presented as mean ± SEM and analyzed using two-tailed t-tests, 1-way ANOVA with Dunnett’s multiple comparison tests, 2-way ANOVA with Sidak’s multiple comparison test or Dunnett’s multiple comparison test and Pearson correlation test. Investigator was not blinded to healthy versus RYR1-RM plasma samples but was blinded to personal identifiable information.

Abbreviations

CDD: Central core disease; Ces1/Ces2: Liver carboxylesterase 1 or 2; CFTD: Congenital fiber-type disproportion; CMN: Centronuclear myopathy; DJI: DOPamine 2 receptor; ER/SR: Endoplasmic reticulum/sarcoplasmic reticulum; ERAD: ER associated degradation; ERS: ER retention/retrieval sequence; FDA: Food and Drug Administration; GPCR: G-protein coupled receptor; IP: Immunoprecipitation; MANF: Mesencephalic astrocyte derived neurotrophic factor; MH: Malignant hyperthermia; MmD: Multi minicore disease; PDI: Protein disulfide isomerase; PRNAII: RNA polymerase II; RYR1: Ryanodine receptor-1; RYR1-RM: RYR1-related myopathies; SEPN1: Selenoprotein 1; SEPN1-RM: SEPN1-related myopathies;Sil1: Nucleotide exchange factor 1; Tg: Thapsigargin; Tm: Tunicamycin; Ube2i: Ubiquitin-conjugating enzyme 2i; UPR: Unfolded protein response.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02368-9.

Additional file 1. Figure S1 Identification of extracellular ERS proteins. A) Blue stain gel of concentrated media from skeletal muscle cells treated with vehicle or 100nM Tg for 8 hours. Arrows indicate qualitative protein increases. B) Table of extracellular ERS proteins identified by mass spectrometry, UniProt accession number, and average Tg-induced response, p-values listed, 2-tailed t-test, vehicle normalized abundance vs Tg normalized abundance.

Additional file 2. Figure S2 Extracellular ERS proteins pre-treated with bromocriptine or dantrolene A) Heat map depicting changes in extracellular ERS protein content when pre-treated with 20µM bromocriptine, or 50µM dantrolene 30 minutes prior to 100nM Tg for 8 hours. B) Western blot of concentrated media collected from T0034 skeletal muscle cell line pre-treated with vehicle, 20µM bromocriptine, or 50µM dantrolene, mean ± SEM, n=2/treatment groups.

Additional file 3. Figure S3 Exodosis is triggered by Tg-induced ER/SR calcium depletion but not Tm-induced ER stress A) MANF HTRF assay of media collected from T0034 skeletal muscle cell line treated with Tg or Tm in maintenance media (A) or mass spectrometry assay media (B) for 8 hours. Extracellular MANF is exclusively elevated following Tg treatment, mean ± SEM, n= 6-12 wells/treatment group. **p<0.01, ***p<0.001, 1-way ANOVA, Dunnett’s multiple comparison test, Tg or Tm vs vehicle. C-F) UPR and ER stress response mRNA levels from T0034 skeletal muscle cell line treated with Tg or Tm in maintenance media (C and E, respectively) or mass spectrometry assay media (D and F, respectively) for 8 hours. Activation of UPR and ER stress response is not sufficient to trigger exodosis, mean ± SEM, n= 3 wells/treatment group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 2-way ANOVA, Dunnett’s multiple comparison test, Tg or Tm vs vehicle.
Acknowledgements
We thank the Johns Hopkins University Mass Spectrometry and Proteomics Core for data acquisition.

Author contributions
E.S.W, L.K.G, B.K.H conceived and executed experiments. E.S.W and L.K.G. analyzed data. E.S.W, L.K.G and B.K.H. wrote manuscript. K.G.M. provided clinical expertise, manuscript review, and human plasma samples. All authors read and approved the final manuscript.

Funding
Open Access funding provided by the National Institutes of Health (NIH) This work was supported by the Intramural Research Programs at the National Institute on Drug Abuse and National Institute of Nursing Research. The study was also supported by National Institutes of Health Bench to Bedside Award.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary files.

Declarations
Ethics approval and consent to participate
Human samples were obtained from the National Institute of Nursing Research, clinical trial identifier NCT02362425. The protocol was approved by the NIH Combined Neuroscience Institutional Review Board. All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Author details
1. National Institute On Drug Abuse, 251 Bayview Blvd, Baltimore, MD 21224, USA. 2. National Institute of Nursing Research, Bethesda, MD, USA.

Received: 3 January 2022 Accepted: 29 May 2022

Published online: 13 June 2022

References
1. Henderson MJ, Wires ES, Trychta KA, Richie CT, Harvey BK. SERCaMP: a carboxy-terminal protein modification that enables monitoring of ER calcium homeostasis. Mol Biol Cell. 2014;25(18):2828–39.

2. Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell Mol Life Sci. 2012;71(1):79–94.

3. Qi L, Tsai B, Arvan P. New insights into the physiological role of endoplasmic reticulum-associated degradation. Trends Cell Biol. 2017;27(6):430–40.

4. Fu S, Yang L, Li H, Hofmann O, Dicker L, Hide W, et al. aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature. 2011;473(7348):528–31.

5. Lemmer IL, Willemsen N, Hilal N, Bartelt A. A guide to understanding endoplasmic reticulum stress in metabolic disorders. Mol Metab. 2021;47:101169.

6. Cribb AE, Peyrou M, Muruganandan S, Schneider L. The endoplasmic reticulum in xenobiotic toxicity. Drug Metab Res. 2005;37(3):405–42.

7. Rayavarapu S, Coley W, Nagaraju K. Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep. 2012;14(3):238–43.

8. Trychta KA, Back S, Henderson MJ, Harvey BK. KDEL Receptors are differentially regulated to maintain the ER proteome under calcium deficiency. Cell Rep. 2018;25(7):1829–40.

9. Trychta KA, Xie B, Verma RK, Xu M, Shi L, Harvey BK. Computational modeling of C-terminal tails to predict the calcium-dependent secretion of endoplasmic reticulum resident proteins. Front Chem. 2021;9:689608.

10. Henderson MJ, Trychta KA, Yang SM, Back S, Yasgar A, Wires ES, et al. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell Rep. 2021;35(4):109040.

11. Witherspoon JW, Meilleur KG. Review of Ryr1 pathway and associated pathomechanisms. Acta Neuropathol Commun. 2016;4(121).

12. Jeyakumar LH, Geaves LA, Ridley BD, Chang P, Atkinson J, Barnett JY, et al. The skeletal muscleryanide receptor isoform 1 is found at the intercalated discs in human and mouse hearts. J Muscle Res Cell Motil. 2002;23(4):285–92.

13. Amburgey K, Mclamara N, Bennett LR, McCormick ME, Acsadi G, Dowling JJ. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol. 2011;70(4):662–5.

14. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.

15. StatPearls. 2021.

16. Todd JJ, Sagar V, Lawal TA, Allen C, Razazgar MS, Shelton MS, et al. Correlation of phenotype with genotypem and protein structure in RYR1-related disorders. J Neurol. 2018;265(11):2506–24.

17. Weiher M, Rueffert H, Koenig F, Olthoff D. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations ile2182Phe and Gly2375Ala. Genet Test. 2003;7(3):203–11.

18. López JR, Linares N, Pessah IN, Allen PD. Enhanced response to caffeine and 4-chloro-m-cresol in malignant hyperthermia-susceptible muscle is related in part to chronically elevated resting [Ca2+]i. Am J Physiol Cell Physiol. 2005;288(3):C606–12.

19. Zhou H, Yamaguchi N, Xu L, Wang Y, Sewry C, Jungbluth H, et al. Characterization of recessive RYR1 mutations in core myopathies. Hum Mol Genet. 2006;15(18):2791–803.

20. Choi RH, Koenig X, Launikonis BS. Dantrolene requires Mg. Proc Natl Acad Sci U S A. 2011;108(18):7481–5.

21. Miller KL, Farmaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16(1):265.

22. Yamazawa T, Kobayashi T, Kurebayashi N, Konishi M, Noguchi S, Inoue T, et al. A novel RYR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke. Nat Commun. 2021;12(1):4293.

23. Einhorn L, Kräpfenbauer K. HTTR: a technology tailored for biomarker determination-novel analytical detection system suitable for detection of specific autoimmune antibodies as biomarkers in nanogram level in different body fluids. EPMA J. 2015, 6:23.

24. Todd JJ, Lawal TA, Witherspoon JW, Chrismer IC, Razazgar MS, Punjabhi M, et al. Randomized controlled trial of. Neurology. 2020;94(13):e1434–44.

25. Mekahli D, Boltynck G, Parys JB, De Smedt H, Missiaen L. Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb Perspect Biol. 2011;3(6).

26. Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman K, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov. 2020;19(2):93–111.

27. Chien CY, Hung YJ, Shieh YS, Hsieh CH, Lu CH, Lin FH, et al. A novel potential biomarker for metabolic syndrome in Chinese adults: circulating calreticulin. PLoS ONE. 2017;12(6):e0179963.

28. Sollazzo D, Forte D, Polverelli N, Perricone M, Romano M, Luatti S, et al. Circulating calreticulin is increased in myelofibrosis: correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly. Mediators Inflamm. 2016;2016:5860657.

29. Wu T, Zhang F, Yang Q, Zhang Y, Liu Q, Jiang W, et al. Circulating mesothelin is regulated in part to chronically elevated resting [Ca2+]i. Acta Neuropathol Commun. 2016;4(1):121.

30. Parakh S, Atkin JD. Novel roles for protein disulphide isomerase in disease states: a double edged sword? Front Cell Dev Biol. 2015;3:30.
33. Galligan JJ, Petersen DR. The human protein disulfide isomerase gene family. Hum Genomics. 2012;6:6.

34. Wang C, Zhu Y, Wu D, Wang Z, Xu X, Shi Y, et al. The role of PDI3 in myogenesis during muscle regeneration. Exp Mol Med. 2020;52(1):105–17.

35. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta. 2004;1699(1–2):35–44.

36. Molinari M, Galli C, Piccaluga V, Pieren M, Paganietto P. Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. J Cell Biol. 2002;158(2):247–57.

37. Trzycka KA, Heathward EJ, Sulima A, Back S, Farokhnia M, Richie CT, et al. Extracellular esterase activity as an indicator of endoplasmic reticulum calcium depletion. Biomarkers. 2018;23(8):756–65.

38. Wires ES, Trycka KA, Back S, Sulima A, Rice KC, Harvey BK. High fat diet disrupts endoplasmic reticulum calcium homeostasis in the rat liver. J Hepatol. 2017;67(5):1009–17.

39. Wu MH, Chen P, Remo BF, Cook EH, Das S, Dolan ME. Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenet. 2003;13(7):425–35.

40. Jäntti M, Harvey BK. Trophic activities of endoplasmic reticulum proteins CDNF and MANF. Cell Tissue Res. 2020;382(1):83–100.

41. Glembotski CC, Thuerauf DJ, Huang C, Večnik JA, Gottlieb RA, Doroudgar S. Misencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic reticulum calcium depletion. J Biol Chem. 2012;287(31):25893–904.

42. Lee CS, Hanna AD, Wang H, Dagnino-Acosta A, Josh AD, Knoblauch M, et al. A chemical chaperone improves muscle function in mice with a RyR1 mutation. Nat Commun. 2017;8:14659.

43. Afroz D, Kumar A. ER stress in skeletal muscle remodeling and myopathies. FEBS J. 2019;286(2):379–98.

44. Girard T, Cavagna D, Padovan E, Spagnoli G, Unwyler A, Zorzato F, et al. B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem. 2001;276(51):48077–82.

45. Ducreux S, Zorzato F, Müller C, Sewry C, Muntoni F, Quinlivan R, et al. Identification of cellular pathogenicity markers for SIL1 mutations linked to Marinesco-Sjögren syndrome. Front Neurol. 2019;10:562.

46. Howard EE, Pasakos SM, Blessos CN, Russell MA, Rodriguez NR. Divergent roles of inflammation in skeletal muscle recovery from injury. Front Physiol. 2020;11:87.

47. Sousa-Victor P, Neves J, Cedron-Craft W, Ventura PB, Liao CY, Riley RR, et al. MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage. J Biol Chem. 2004;279(42):43838–46.

48. Howard EE, Pasakos SM, Blessos CN, Russell MA, Rodriguez NR. Divergent roles of inflammation in skeletal muscle recovery from injury. Front Physiol. 2020;11:87.

49. Villar-Quiles RN, von der Hagen M, Mähre C, Gonzalez V, Donkervoort S, et al. Extracellular esterase activity as an indicator of endoplasmic reticulum calcium depletion. Biomarkers. 2018;23(8):756–65.

50. Jäntti M, Harvey BK. Trophic activities of endoplasmic reticulum proteins CDNF and MANF. Cell Tissue Res. 2020;382(1):83–100.

51. Ichhaporia VP, Kim J, Kavdia K, Vogel P, Horner L, Frase S, et al. SIL1, the endoplasmic reticulum-localized BiP co-chaperone, plays a crucial role in maintaining skeletal muscle proteostasis and physiology. Dis Model Mech. 2018;11(5).

52. Gatz C, Hathiari D, Münchberg U, Buchkremer S, Labisch T, Munro B, et al. Identification of cellular pathogenicity markers for SIL1 mutations linked to Marinesco-Sjögren syndrome. Front Neurol. 2019;10:562.

53. Thorner MO, Chait A, Aitken M, Benker G, Bloom SR, Mortimer CH, et al. Bromocriptine treatment of acromegaly. Br Med J. 1975;4(5953):299–303.

54. Calne DB, Teychenne PF, Cleaver LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974;4(5942):442–4.

55. Eshima H, Miura S, Nakaoka Y, Kato S, Hatakeyama K, Poole DC, Kano Y. Improved skeletal muscle Ca2+-H+ regulation in vivo following contractions in mice overexpressing PGC-1-alpha. Am J Physiol Regul Integr Comp Physiol. 2017;312(6):R1017–28.

56. Gutierrez-Martin Y, Martin-Romero FJ, Henao F. Store-operated calcium entry in differentiated C2C12 skeletal muscle cells. Biochim Biophys Acta. 2005;1711(1):33–40.

57. Treves S, Vukcevic M, Griesser J, Armstrong CF, Zhu MX, Zorzato F. Agonist-activated Ca2+ influx occurs at stable plasma membrane and endoplasmic reticulum junctions. J Cell Sci. 2010;123(Pt 23):4170–81.

58. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet. 2001;10(25):2879–87.

59. Cachexus M, Blum A, Sebastien M, Wozny AS, Brocard J, Mamchaoui K, et al. Functional characterization of a central core disease RyR1 mutation (p.Y4864H) associated with quantitative defect in RyR1 Protein. J Neuro-muscul Dis. 2015;2(4):421–32.

60. Lawal TA, Wires ES, Terry NL, Dowling JJ, Todd JJ. Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990–2019. Orphanet J Rare Dis. 2020;15(1):113.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.